NCT01927198已完成2 期
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 172
- 主要终点
- Efficacy of RDEA3170 monotherapy at Week 12
研究概览
简要总结
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
详细描述
This monotherapy study is the initial Phase 2 study for RDEA3170 and is designed to compare the safety and efficacy of multiple dose levels of RDEA3170 with placebo when given for up to 24 weeks to subjects with gout. The placebo control for RDEA3170 is included in this study to minimize bias in study assessments and monitoring. Further, to accomplish the goal of understanding the safety profile of RDEA3170, it is important to compare RDEA3170 monotherapy with placebo for at least 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject meets the diagnosis of gout per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
- •Subject has a serum urate level ≥ 6.5 mg/dL and ≤ 10.0 mg/dL during the Screening Period.
- •Subject has a body mass index < 40 kg/m2.
排除标准
- •Subject is pregnant or breastfeeding. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
- •Subject has a history or suspicion of kidney stones.
- •Subject has a history or suspicion of drug abuse within the past 5 years.
- •Subject has a history of symptomatic myositis/myopathy or rhabdomyolysis.
- •Subject has a known or suspected human immunodeficiency virus infection.
- •Subject has a positive test for active hepatitis B or hepatitis C infection.
- •Subject has a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ Grade 1 cervical cancer.
- •Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
- •Subject has a QT interval corrected for heart rate according to Fridericia's formula > 450 msec during the Screening Period, confirmed by a repeat assessment.
- •Subject has uncontrolled hypertension.
- •Subject has an estimated creatinine clearance < 60 mL/min.
- •Subject has an alkaline phosphatase > 2.0 x upper limit of normal during the Screening Period.
- •Subject has active liver disease or impaired hepatic function.
- •Subject is receiving chronic treatment with more than 325 mg salicylates per day.
- •Subject has a medical condition that requires or may require systemic immunosuppressive (eg, chronic low-dose oral prednisone) or immunomodulatory treatment.
- •Subject is unable to take colchicine for gout flare prophylaxis.
- •Subject is receiving strong or moderate CYP3A inhibitors, p-glycoprotein inhibitors, or digoxin.
- •Subject received any strong enzyme- inducing drug or product (eg, rifampin, rifabutin, phenytoin, phenobarbital, St. John's Wort) within 2 months prior to Day 1 or refuses to refrain from taking these medications until the end of the study.
- •Subject received an investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to the Screening Period.
- •Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
研究组 & 干预措施
RDEA3170 5 mg qd
Experimental
No titration.
干预措施: RDEA3170 5 mg (Drug)
RDEA3170 10 mg qd
Experimental
Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
干预措施: RDEA3170 10 mg (Drug)
RDEA3170 12.5 mg qd
Experimental
Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
干预措施: RDEA3170 12.5 mg (Drug)
Placebo
Placebo Comparator
Placebo group
干预措施: Placebo (Drug)
结局指标
主要结局
Efficacy of RDEA3170 monotherapy at Week 12
时间窗: Week 12
Percent change from baseline in serum urate levels at Week 12.
次要结局
- Efficacy of RDEA3170 monotherapy at Week 24(Week 24)
- Incidence of treatment-emergent adverse events and change from baseline in laboratory values, vital signs, and electrocardiograms(8 months)
研究者
相似试验
已完成
1 期
Single and Multiple Dose Study in Japanese SubjectsGoutNCT01872832Ardea Biosciences, Inc.46
已完成
3 期
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)Arthritis, GoutyGout ChronicGoutHyperuricemiaNCT06439602Arthrosi Therapeutics818
已完成
3 期
Combining Lesinurad With Allopurinol in Inadequate RespondersGoutNCT01510158Ardea Biosciences, Inc.607
已完成
3 期
Combining Lesinurad With Allopurinol in Inadequate RespondersGoutNCT01493531Ardea Biosciences, Inc.610
已完成
3 期
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatTophaceous GoutNCT01510769Ardea Biosciences, Inc.330